RCMNet: A deep learning model assists CAR-T therapy for leukemia
Acute leukemia is a type of blood cancer with a high mortality rate. Current
therapeutic methods include bone marrow transplantation, supportive therapy,
and chemotherapy. Although a satisfactory remission of the disease can be
achieved, the risk of recurrence is still high. Therefore, novel treatments are
demanding. Chimeric antigen receptor-T (CAR-T) therapy has emerged as a
promising approach to treat and cure acute leukemia. To harness the therapeutic
potential of CAR-T cell therapy for blood diseases, reliable cell morphological
identification is crucial. Nevertheless, the identification of CAR-T cells is a
big challenge posed by their phenotypic similarity with other blood cells. To
address this substantial clinical challenge, herein we first construct a CAR-T
dataset with 500 original microscopy images after staining. Following that, we
create a novel integrated model called RCMNet (ResNet18 with CBAM and MHSA)
that combines the convolutional neural network (CNN) and Transformer. The model
shows 99.63% top-1 accuracy on the public dataset. Compared with previous
reports, our model obtains satisfactory results for image classification.
Although testing on the CAR-T cells dataset, a decent performance is observed,
which is attributed to the limited size of the dataset. Transfer learning is
adapted for RCMNet and a maximum of 83.36% accuracy has been achieved, which is
higher than other SOTA models. The study evaluates the effectiveness of RCMNet
on a big public dataset and translates it to a clinical dataset for diagnostic
applications.